Wellington Management Group
CRNX

Wellington Management Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Wellington Management Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267M Sell
7,131,084
-1,026,120
-13% -$38.1M 0.05% 328
2026
Q1 		$296M Buy
8,157,204
+119,315
+1% +$5.33M 0.06% 293
2025
Q4 		$374M Sell
8,037,889
-344,102
-4% -$15.3M 0.07% 252
2025
Q3 		$349M Buy
8,381,991
+2,574,683
+44% +$82.3M 0.06% 277
2025
Q2 		$167M Sell
5,807,308
-1,084,089
-16% -$33.5M 0.03% 394
2025
Q1 		$231M Sell
6,891,397
-59,170
-0.9% -$2.21M 0.04% 315
2024
Q4 		$355M Buy
6,950,567
+2,490,876
+56% +$139M 0.07% 246
2024
Q3 		$228M Sell
4,459,691
-160,722
-3% -$8.29M 0.04% 362
2024
Q2 		$207M Buy
4,620,413
+1,648,831
+55% +$76.1M 0.04% 375
2024
Q1 		$139M Sell
2,971,582
-273,523
-8% -$10.7M 0.02% 476
2023
Q4 		$115M Sell
3,245,105
-395,130
-11% -$12.1M 0.02% 526
2023
Q3 		$108M Buy
3,640,235
+38,523
+1% +$794K 0.02% 503
2023
Q2 		$64.9M Sell
3,601,712
-33,814
-0.9% -$674K 0.01% 652
2023
Q1 		$58.4M Buy
3,635,526
+831,041
+30% +$15.4M 0.01% 659
2022
Q4 		$51.3M Buy
2,804,485
+171,474
+7% +$3.02M 0.01% 678
2022
Q3 		$51.7M Buy
2,633,011
+809,413
+44% +$16.5M 0.01% 663
2022
Q2 		$34M Buy
1,823,598
+794,234
+77% +$15.9M 0.01% 790
2022
Q1 		$22.6M Sell
1,029,364
-40,908
-4% -$828K ﹤0.01% 989
2021
Q4 		$30.4M Buy
1,070,272
+157,201
+17% +$3.88M ﹤0.01% 986
2021
Q3 		$19.2M Buy
913,071
+167,684
+22% +$3.51M ﹤0.01% 1101
2021
Q2 		$14.1M Buy
745,387
+193,220
+35% +$3.4M ﹤0.01% 1181
2021
Q1 		$8.44M Sell
552,167
-4,468
-0.8% -$69.3K ﹤0.01% 1284
2020
Q4 		$7.85M Buy
556,635
+118,879
+27% +$1.66M ﹤0.01% 1234
2020
Q3 		$6.86M Buy
437,756
+126,475
+41% +$1.93M ﹤0.01% 1199
2020
Q2 		$5.45M Buy
+311,281
New +$5.31M ﹤0.01% 1196

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group's CRNX Position: Q2 2026 in Review

Wellington Management Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 13% in Q2 2026, selling an estimated $38.1M and leaving 7,131,084 shares worth $267M. The position accounts for 0.05% of the portfolio, ranked #328.

Wellington Management Group first reported a position in CRNX in Q2 2020 and has held it in 25 quarters since. The position peaked at $374M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Wellington Management Group held 7,131,084 shares of Crinetics Pharmaceuticals worth $267M as of Q2 2026.
  • Wellington Management Group sold 1,026,120 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $38.1M.
  • Crinetics Pharmaceuticals made up 0.05% of Wellington Management Group's portfolio in Q2 2026, its #328 holding.
  • Wellington Management Group first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Wellington Management Group's Crinetics Pharmaceuticals position peaked at $374M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.